Subscribe
roschetzkyistockphoto
roschetzky / iStockphoto
5 March 2019Americas

‘Breaking’ patents would harm innovation: think tank

The Information Technology and Innovation Foundation (ITIF) think tank has called on the US National Institutions of Health (NIH) to maintain IP protection amid calls to “break” patents in order to lower drug prices.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank
23 June 2021   Making sense of the newest Section 337 developments will be a key focus of The American Conference Institute’s 13th Annual Practitioners’ Think Tank on ITC Litigation and Enforcement.
Americas
Gilead claims US government PrEP patents are invalid
20 May 2019   Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
Big Pharma
US patent reforms could re-establish gene patent eligibility, industry experts warn
6 June 2019   A group of more than 100 medical, scientific, patient advocacy and women’s health organisations have opposed a recent proposal to amend section 101 of the US Patent Act.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Biotechnology
Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank
23 June 2021   Making sense of the newest Section 337 developments will be a key focus of The American Conference Institute’s 13th Annual Practitioners’ Think Tank on ITC Litigation and Enforcement.
Americas
Gilead claims US government PrEP patents are invalid
20 May 2019   Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
Big Pharma
US patent reforms could re-establish gene patent eligibility, industry experts warn
6 June 2019   A group of more than 100 medical, scientific, patient advocacy and women’s health organisations have opposed a recent proposal to amend section 101 of the US Patent Act.

More on this story

Biotechnology
Conference preview: ACI breaks down Section 337 at the 13th Annual Practitioners’ Think Tank
23 June 2021   Making sense of the newest Section 337 developments will be a key focus of The American Conference Institute’s 13th Annual Practitioners’ Think Tank on ITC Litigation and Enforcement.
Americas
Gilead claims US government PrEP patents are invalid
20 May 2019   Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
Big Pharma
US patent reforms could re-establish gene patent eligibility, industry experts warn
6 June 2019   A group of more than 100 medical, scientific, patient advocacy and women’s health organisations have opposed a recent proposal to amend section 101 of the US Patent Act.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York